濮阳东方医院男科治早泄评价比较好濮阳东方医院治疗阳痿价格收费合理,濮阳东方医院男科看早泄评价好很专业,濮阳东方医院治阳痿价格透明,濮阳东方医院男科治阳痿评价好收费低,濮阳东方医院男科看阳痿咨询电话,濮阳东方医院妇科做人流收费很低,濮阳东方医院看早泄价格便宜

LOS ANGELES, June 5 (Xinhua) -- U.S. researchers have developed two new drugs that can prolong the lives of patients with advanced melanoma, it was announced on Sunday.Research on both drugs was presented at the on-going annual meeting of the American Society of Clinical Oncology in Chicago, according to HealthDay News.This is the first big news in years for treatment of melanoma, one of the deadliest forms of skin cancer and one that is notoriously difficult to treat, let alone cure, the report said.The first treatment, vemurafenib, inhibits a gene mutation harbored in half of all melanoma patients, but is not yet approved by the U.S. Food and Drug Administration.The other drug, Yervoy (ipilumumab), is an immune system therapy that won approval in March."The March FDA approval of ipilumumab (Yervoy) was the first new drug approval for melanoma in 13 years," said Tim Turnham, executive director of the Melanoma Research Foundation.The two drugs were developed by researchers at Memorial Sloan- Kettering Cancer Center in New York City, the report said."This is really a huge step toward personalized care in melanoma," Dr. Paul Chapman, lead author of the first study and the attending physician in the melanoma/sarcoma service at Memorial Sloan-Kettering, said in a statement. "This (vemurafenib) is the first successful melanoma treatment tailored to patients who carry a specific gene mutation in their tumor, and could eventually become one of only two drugs available that improves overall survival in advanced cancers.""Having two trials that show a benefit in survival in patients with melanoma, both of these in first-line settings -- we weren't here just a few years ago," said Dr. Stephen Hodi, director of the Melanoma Center at Dana Farber Cancer Institute in Boston. "These are huge, paradigm-shifting results for the field."In the vemurafenib trial, sponsored by the drug's makers, researchers randomly assigned 675 patients with advanced, inoperable melanoma to receive either the chemotherapy drug dacarbazine or vemurafenib. Vemurafenib targets the V600E mutation in the BRAF gene.At the three-month mark, patients taking vemurafenib were 63 percent less likely to die and 74 percent less likely to die or see their cancer return, compared to patients taking dacarbazine alone.Few patients had side effects in the vemurafenib group, although some did develop squamous cell carcinoma, a less dangerous form of skin cancer.This is the first drug that has been proven superior to chemotherapy in this group of hard-to-treat patients, the researchers said."There was such a substantial benefit that we recommended that patients cross over," Chapman said at a Sunday news briefing. "It' s unprecedented to report a trial this early. The median follow-up time was three months." Yet the differences between the two groups became evident almost immediately.Dr. Lynn Schuchter, co-moderator of the briefing and division chief of hematology-oncology at Abramson Cancer Center of the University of Pennsylvania in Philadelphia, said symptoms subsided in some patients almost immediately, enabling them to cut back on pain medication in just 72 hours."The median time to progression with dacarbazine was 1.6 months versus three months with vemurafenib, which is a huge difference," said Chapman.In the second study, about 500 patients were randomly picked to receive Yervoy plus dacarbazine or dacarbazine alone.Those taking both drugs lived a median of 11.2 months compared to 9.1 months for those taking dacarbazine alone. Time to recurrence of disease was about the same for both groups: 2.8 months and 2.6 months, respectively.Almost half of those taking the combination therapy were alive after one year, compared to 36.3 percent in the other group. After two years, the rates were 28.5 percent and 17.9 percent, respectively.By three years out, 20.8 percent of those in the combination group were alive compared with 12.2 percent of those taking chemotherapy alone.This is the first study to combine chemotherapy and immunotherapy both safely and effectively.A study to test vemurafenib in combination with Yervoy has already begun, according to HealthDay News.

BEIJING, Aug. 30 (Xinhua) -- China's second moon orbiter, the Chang'e-2, has arrived in outer space about 1.5 million km away from Earth and is now orbiting the second Lagrange Point (L2), where gravity from the sun and Earth balances the orbital motion of a satellite, Chinese scientists said Tuesday.Chang'e-2 entered L2's orbit at 11:27 p.m. last Thursday after spending 77 days traveling away from its previous orbital path around the moon, according to the State Administration of Science, Technology and Industry for National Defence (SASTIND).The SASTIND said that China is now the world's third country or organization to successfully put a spacecraft into orbit around L2, after the European Space Agency (ESA) and the National Aeronautics and Space Administration (NASA) of the United States.The Chang'e-2 orbiter will carry out exploration activities around L2 in the coming year, SASTIND said.There are five so-called "Lagrange Points" about 1.5 million km way from the Earth in the exact opposite direction from the sun. Putting a spacecraft at any of these points allows it to stay in a fixed position relative to the Earth and sun with a minimal amount of energy needed for course correction.The orbiter completed all of its assigned tasks after blasting off on Oct. 1, 2010, according to the SASTIND. Although the orbiter was only supposed to remain in space for six months, the SASTIND decided to assign additional tasks to it, as it still had fuel in its reserve tanks.Traveling into outer space from the moon's orbit was one of the orbiter's most important missions, according to the SASTIND.Before arriving at its current position in outer space, the Chang'e-2 took photos of the northern and southern poles of the moon. It then descended to a lower orbit, approximately 15 km away from the moon's surface, where it captured high-resolution images of the Sinus Iridum, or "Bay of Rainbows," an area where future moon probes may land.The SASTIND is reportedly planning to launch measure and control stations into outer space by the end of the second half of next year. The Chang'e-2 will be used to test the two stations' functionality at that time.China's ambitious three-stage moon mission will include a moon landing, as well as the launch of a moon rover during the second stage, which is scheduled to take place in 2012. During the third phase, another rover will land on the moon and return to Earth with lunar soil and stone samples for scientific research around 2017.China does not currently have a timetable in place for a manned moon landing. It launched its first lunar probe, the Chang'e-1, in October 2007.In 2003, China became the third country after Russia and the United States to send a human into space. Two more manned space missions followed, the most recent of which took place in 2008.0 The Chang'e probes are named after the Chinese legendary goddess of the moon.

SAN FRANCISCO, Aug. 9 (Xinhua) -- Nokia is planning to stop selling its low-end phones and smartphones in the United States, instead focusing on products using Microsoft's Windows Phone platform, U.S. media reported on Tuesday.The Finnish handset maker will end sales of its low-end Series 40 phones and smartphones based on the Symbian mobile operating system in the United States and Canada, as it needs to put all of its efforts into the Windows Phone products which are due out later this year, Chris Weber, head of Nokia's U.S. subsidiary, told technology news site All Things Digital."When we launch Windows Phones we will essentially be out of the Symbian business, the S40 business, etc.," Weber said.Staff members speak to trade visitors at the Nokia booth at the CommunicAsia expo in Singapore June 21, 2011.In February, Nokia and Microsoft announced plans to form a broad strategic partnership, under which Nokia agrees to adopt Windows Phone as its principal smartphone strategy.North America is a priority for Nokia, Weber noted, in part because it is a key market for Microsoft and also because Nokia sees it as a key to winning in the smartphone battle globally."We'll develop for North America and make the phones globally available and applicable," Weber said.In another development, technology blog Engadget and other U.S. media on Tuesday reported that Nokia will not bring N9, its first smartphone running the Linux-based mobile operating system MeeGo, to the U.S. market."After the very positive reception to the launch of the Nokia N9, the product is now being rolled out in countries around the world. At this time we will not be making it available in the U.S., " Nokia said in a statement.

He also said that China's track record of sharing knowledge with the World Bank was creating a "catalyst for consensus" and that placed the institutions in good stead to benefit from China's economic consistence."The Chinese policy mix includes a tool box of administrative measures ... In general, one of the lessons that the United States and others can learn (from China) is that to have supervisory policies for bank regulatory systems can be a useful part of the tool set."Aside from hinting that over-heating global real estate markets could benefit from China's regulatory tightening, Zoellick suggested if China moved to more market-exposed decision making, he hoped China's bank regulators would not step too far back."Over time China will be better served to move to more precise and market signals than more administration-based decisions. Over time China will want to move to more market based decisions ... but I don't want this to be interpreted that supervisors don't have to supervise," he said.

CAIRO, July 6 (Xinhua) -- Egypt's Central Administration of Agricultural Quarantine has denied again that the country's fenugreek seeds exported to Europe caused the E.coli infections which have claimed dozens of lives.The Egyptian authorities took and analyzed fenugreek seeds samples from the warehouse of the said Egyptian exporter and all results were negative by the strain, a statement posted on the official website of Egypt's Agricultural Ministry said on Wednesday."E.coli strain has not been reported in Egypt and no illness cases have been found," it added.If fenugreek seeds sprouts are suspected to be contaminated with E.coli pathogenic strain, it could be related to different handling processes, such as the re-packing or water used for sprouting, the statement said.The European Union (EU) on Tuesday agreed to ban the import of certain types of seeds from Egypt as Egyptian fenugreek seeds were reported to be linked with the outbreak of E.coli in Europe.The European Food Safety Authority (EFSA) published early Tuesday a report from its task force on the E.coli outbreaks in Germany and France, indicating that fenugreek seeds imported from Egypt is the most likely source of the outbreaks.The E.coli outbreak has killed over 50 people in Europe since it was first reported in late May.Russia's food safety watchdog Rospotrebnadzor has also banned the import of certain types of produce from Egypt over food safety concerns, a Russian official said on Wednesday.Egypt's Ministry of Agriculture refuted the claims of Egypt being the source of E.coli Friday.